page-up-arrow
page-down-arrow
Background

Was this page useful?

*Required Field
Rating *
Rating            

Research / News & Events/ News

 

 

 

News

News
« Back to listings

Researchers at St. Joseph’s Healthcare Hamilton are evaluating the effectiveness of a new personalized medicine technology that uses a simple cheek swab to determine the best medication for patients diagnosed with depression, schizophrenia, anxiety, PTSD, bipolar disorder and other mental health conditions.

Dr. Jean-Eric Tarride and his colleagues at PATH (Programs for Assessment of Technology in Health) are partnering with the MaRS EXCITE program and the CAMH (Centre for Addiction and Mental Health) to determine the therapeutic value of Assurex Canada’s GeneSight tool – helping to ensure that those diagnosed with mental health conditions in Ontario receive treatments best suited to their own genetic makeup.

Working together with industry partners allows our researchers to help bring safe and effective treatments from the testing stage to hospitals like ours.

Read more about how our researchers are testing GeneSight here.

Comments are closed.